Physician profile
Robert G Bishop
NPI 1013902782
$10,771.42
in general payments reported to CMS, 2019-2025
57 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $261 · 2021: $1,055 · 2022: $1,531 · 2023: $1,834 · 2024: $2,196 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,372.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,801.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,111.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $907.44 | 2019-2025 | |
| Glaxosmithkline, LLC. | $732.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $677.69 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.91 | 2019-2025 | Jardiance, Synjardy, Jascayd |
| Novartis Pharmaceuticals Corporation | $466.40 | 2019-2025 | |
| Exact Sciences Corporation | $459.84 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $396.07 | 2021-2025 | |
| Amgen INC. | $327.17 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $301.80 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $266.02 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $229.16 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.40 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $161.04 | 2019-2025 | Lagevrio, Capvaxive, Gardasil 9 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.